Carrolee Barlow, MD, PhD

    Chief Executive Officer
    Parkinson’s Institute and Clinical Center

    Carrolee Barlow, MD, PhD is a renowned expert in neuroscience and neurodegeneration. She is the Parkinson’s Institute and Clinical Center’s Chief Executive Officer (CEO). She joined the Parkinson’s Institute in February 2014 and is one of only two CEO’s who have run the organization since it was founded in 1988 by Dr. J. W. Langston.

    Dr. Barlow’s career has focused on clinical care, laboratory and clinical research, academia, and industry. She is the founder and former Chief Scientific Officer and Chief Medical Officer of Br`ainCells, Inc. in San Diego, California, a biotechnology company focused on the discovery and development of small molecules that stimulate adult hippocampal neurogenesis for the treatment of neurological and psychiatric disease using human neural stem cell technology. Prior to BrainCells, Dr. Barlow was a professor at Salk Institute for Biological Studies, running a lab that used animal models to study neuro-diseases, and eventually helping to establish the field of neurogenomics. She then supervised neuroscience biology, global exploratory, licensing, and full phase efforts as the Director of Molecular Neuroscience and the Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories. Moreover, she serves as an advisory board member for several biotechnology companies and disease foundations.

    Dr. Barlow received her MD from the University of Utah and completed her residency in Internal Medicine at The New York Hospital, Cornell Medical Center. She went on to obtain a PhD in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden. Shortly thereafter, she joined the National Institute of Health and completed medical sub-specialty training in the field of endocrinology and a postdoctoral fellowship in neurogenetics at the National Human Genome Research Institute.

    Dr. Barlow’s goal is to find solutions and treatments for Parkinson’s disease in the same way she has done with other diseases. Working with the FDA and others, she is finding ways to transform clinical studies for neurodegenerative diseases by evaluating the science and designing studies in a way that turns research into new treatments.